Finabase

    • Login
    • Categories
    Home Watchlists Portfolios Map Forex Futures Crypto Comparisons Alerts Screeners Backtests vTrading Settings Forum
    1. Home
    2. OBSV
    • Alert
    • Note
    OBSV
    ObsEva SA
    0.21
    -
    0.00
    0.93%
    14 x 0.21
    8 x 0.22
    bid
    ask
    11 @ 03:59 PM
    0.21+0.00 (0.90%)
    Bearish 8
    Bullish 31
    sentiment
    0.21
    day range
    0.22
    0.14
    52 week range
    2.08
    03:59 PM
    V: 831.39K
    C: 0.21
    L: 0.21
    H: 0.22
    O: 0.22
    loading chart ...
    • 1d
    • 5d
    • 1m
    • 3m
    • 6m
    • ytd
    • 1y
    • 2y
    • 5y
    • max
    • PDF
    • Full Chart
    • Stats
    • Watchlist
    • Portfolio
    Prev Close0.21
    Open0.22
    Low0.21
    High0.22
    Volume831.39K
    Avg. Volume1.84M
    Market Cap22.06M
    Inst. Own14.12%
    Beta0.40
    Short Ratio1.30
    Div & Yield0.00 /
    EPS-0.64
    P/E
    1yr Target6.50
    50day MA0.18
    200day MA0.70
    ^DJI
    Dow Jones Industrial Average
    33926.00
    04:54 PM
    -
    127.90
    0.38%
    ^IXIC
    NASDAQ Composite
    12007.00
    05:15 PM
    -
    193.80
    1.59%
    ^GSPC
    S&P 500
    4136.48
    04:54 PM
    -
    43.28
    1.04%
    AAPL
    154.40
    -0.10 (0.06%)
    Apple Inc.
    154.50
    17 @ 04:00 PM
    11 x 154.32
    22 x 154.43
    +
    3.68
    2.44%
    GOOG
    105.21
    -0.01 (0.01%)
    Alphabet Inc.
    105.22
    10 @ 04:00 PM
    11 x 105.06
    8 x 105.26
    -
    3.58
    3.29%
    AMZN
    102.93
    -0.46 (0.44%)
    Amazon.com, Inc.
    103.39
    11 @ 04:00 PM
    12 x 102.95
    10 x 102.91
    -
    9.52
    8.43%
    MSFT
    258.20
    -0.15 (0.06%)
    Microsoft Corporation
    258.35
    12 @ 04:00 PM
    13 x 258.00
    10 x 258.09
    -
    6.25
    2.36%
    BABA
    106.40
    +0.07 (0.07%)
    Alibaba Group Holding Limited
    106.33
    10 @ 04:01 PM
    11 x 0.00
    8 x 0.00
    -
    3.41
    3.11%
    NFLX
    365.90
    +0.00 (0.00%)
    Netflix, Inc.
    365.90
    9 @ 04:00 PM
    10 x 365.60
    8 x 365.90
    -
    0.99
    0.27%
    TSLA
    192.72
    +2.74 (1.44%)
    Tesla, Inc.
    189.98
    10 @ 04:00 PM
    11 x 192.72
    8 x 192.77
    +
    1.71
    0.91%
    NVDA
    210.75
    -0.25 (0.12%)
    NVIDIA Corporation
    211.00
    10 @ 04:00 PM
    9 x 210.76
    10 x 211.00
    -
    6.09
    2.81%
    AMD
    85.98
    -0.11 (0.13%)
    Advanced Micro Devices, Inc.
    86.09
    9 @ 04:00 PM
    10 x 85.98
    8 x 85.95
    -
    2.22
    2.51%
    MU
    62.29
    -0.12 (0.19%)
    Micron Technology, Inc.
    62.41
    12 @ 04:00 PM
    12 x 62.20
    12 x 62.50
    -
    0.76
    1.20%
    SPY
    411.63
    -0.72 (0.17%)
    SPDR S&P 500 ETF Trust
    412.35
    11 @ 04:00 PM
    9 x 411.38
    12 x 411.69
    -
    4.43
    1.06%
    TQQQ
    25.39
    -0.13 (0.51%)
    ProShares UltraPro QQQ
    25.52
    12 @ 04:00 PM
    12 x 25.39
    12 x 25.45
    -
    1.39
    5.17%
    BRK-A
    466755.00
    +0.00 (0.00%)
    Berkshire Hathaway Inc.
    466755.00
    10 @ 04:02 PM
    12 x 0.00
    8 x 0.00
    -
    5360.00
    1.14%
    Day Gain
    Gain
    Market Val
    Costs
    Cash
    Portfolio
    Realized
    Dividend
    • Summary
    • Discussion
    • News
    • Signals
    • Financials
    • Alerts
    • Notes
    • Chart
    • Backtest
    News ...
    Medicxi Ventures Management (Jersey) Ltd Buys 3, Sells 2 in 4th ... news.google.com •
    ObsEva SA (OBSV) expanding its growth trajectory ahead – Sete ... news.google.com •
    ObsEva SA (OBSV) Reports Q3 Loss, Lags Revenue Estimates zacks.com •
    Hot Penny Stocks For Your Buy List in September? 3 to Watch pennystocks.com •
    All You Need to Know About ObsEva SA (OBSV) Rating Upgrade to Buy zacks.com •
    Why Is ObsEva (OBSV) Stock Down 70% Today? investorplace.com •
    Profile ...
    ObsEva SA, a biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy. It is developing Linzagolix, an oral gonadotropin releasing hormone receptor antagonist that is in Phase III clinical trial for the treatment of pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. The company is also involved in developing Ebopiprant, an oral and selective prostaglandin F2a, or PGF2a receptor antagonist, which is in Phase II clinical trial as a once daily treatment for preterm labor in weeks 24 to 34 of gestational age; and Nolasiban, an oral oxytocin receptor antagonist that is in Phase I clinical trial to enhance clinical pregnancy and live birth rates in women undergoing in vitro fertilization. ObsEva SA was founded in 2012 and is headquartered in Geneva, Switzerland.
    Earning ...
    Date For Estimate Reported Surprise surprise %
    2023-03-09 2022-12 -0.08 N/A N/A N/A
    2022-12-01 2022-09 -0.14 -0.13 0.01 7.14%
    2022-08-17 2022-06 -0.22 -0.16 0.06 27.27%
    2022-05-17 2022-03 -0.25 -0.14 0.11 44.00%
    2022-03-10 2021-12 -0.22 -0.26 -0.04 -18.18%
    2021-11-04 2021-09 -0.22 0.01 0.23 104.55%
    Upgrade / Downgrade ...
    Date Firm Action From To
    2022-08-30 HC Wainwright & Co. Downgrade Buy Neutral
    2022-06-03 Cantor Fitzgerald Upgrade Overweight
    2022-04-26 Canaccord Genuity Upgrade Buy
    2022-03-28 Aegis Capital Upgrade Buy
    2022-03-28 HC Wainwright & Co. Upgrade Buy
    2021-11-29 HC Wainwright & Co. Upgrade Buy
    Institution Ownership ...
    Report Date Organization Position Value Percentage
    2022-09-29 Sofinnova Investments, Inc. 4.75M 1.01M 4.37%
    2022-09-29 NEA Management Company, LLC 4.59M 972.81K 4.22%
    2022-09-29 Credit Suisse AG 1.58M 334.51K 1.45%
    2022-12-30 Zurcher Kantonalbank (Zurich Cantonalbank) 668.49K 141.79K 0.62%
    2022-09-29 Pictet Asset Management SA 371.60K 78.82K 0.34%
    2022-09-29 Blackrock Inc. 326.83K 69.32K 0.30%
    Fund Ownership ...
    Report Date Organization Position Value Percentage
    2022-11-29 Fidelity NASDAQ Composite Index Fund 82.23K 17.44K 0.08%
    Loading More Posts
    • Oldest to Newest
    • Newest to Oldest
    • Most Votes
    Reply
    • Reply as topic
    Log in to reply
    This topic has been deleted. Only users with topic management privileges can see it.
    • sandc212
      sandc212 last edited by

      $AMTD $BOXD $OBSV

      1 Reply Last reply Reply Quote 0
      • J
        jody.elrod 0 last edited by

        Something’s cooking!

        1 Reply Last reply Reply Quote 0
        • P
          parikshitparmar191 last edited by

          Here we go

          1 Reply Last reply Reply Quote 0
          • P
            parikshitparmar191 last edited by

            Finally the time is here
            November December and January are going to be crazy
            Loading up ever week

            1 Reply Last reply Reply Quote 0
            • m.caglin
              m.caglin last edited by

              This stock April 30 open 3.92 after rocked 255.88 marked cap close after marked close good luck every one

              1 Reply Last reply Reply Quote 0
              • drsabariuma
                drsabariuma last edited by

                Sell if it breaks 4

                1 Reply Last reply Reply Quote 0
                • drsabariuma
                  drsabariuma last edited by

                  Alert a buy at 3.71 and if anyone is interested in learning dm me hari25sabari@gmail.com

                  1 Reply Last reply Reply Quote 0
                  • drsabariuma
                    drsabariuma last edited by

                    Alert a buy at 3.71 and if anyone is interested in learning dm me hari25sabari@gmail.com

                    1 Reply Last reply Reply Quote 0
                    • drsabariuma
                      drsabariuma last edited by

                      Not halted

                      1 Reply Last reply Reply Quote 0
                      • drsabariuma
                        drsabariuma last edited by

                        Needs to hold above 4.19

                        1 Reply Last reply Reply Quote 0
                        • drsabariuma
                          drsabariuma last edited by

                          Alert a buy at 3.71 and if anyone is interested in learning dm me hari25sabari@gmail.com

                          1 Reply Last reply Reply Quote 0
                          • drsabariuma
                            drsabariuma last edited by

                            Alert a buy at 3.71 and if anyone is interested in learning dm me hari25sabari@gmail.com

                            1 Reply Last reply Reply Quote 0
                            • drsabariuma
                              drsabariuma last edited by

                              Alert a buy at 3.71 and if anyone is interested in learning dm me hari25sabari@gmail.com

                              1 Reply Last reply Reply Quote 0
                              • drsabariuma
                                drsabariuma last edited by

                                Need to break 4.19

                                1 Reply Last reply Reply Quote 0
                                • M
                                  maynall44 last edited by

                                  Seems like someone wants this company for cheap. As soon as they publish there results all of a sudden I start seeing a lot of not so good news. Something don’t smell right!!

                                  1 Reply Last reply Reply Quote 0
                                  • M
                                    maynall44 last edited by

                                    Just hold strong...a good partner deal will send this to the moon. The company only have a market cap of $140 million. Approval of this drugs in Europe and the US will send this well over $1 billion in valuation.

                                    1 Reply Last reply Reply Quote 0
                                    • cpp3004
                                      cpp3004 last edited by

                                      $OBSV

                                      MAKES NO SENSE

                                      1 Reply Last reply Reply Quote 0
                                      • M
                                        maynall44 last edited by

                                        ObSeva Announces Positive Pilot Study Results From Linzagolix In Adenomyosis

                                        Obseva SA (NASDAQ: OBSV) announced the publication in the journal Fertility and Sterility of a case report from a pilot study assessing the use of linzagolix for the treatment of uterine adenomyosis. The study showed the patient treated with linzagolix saw alleviation of symptoms such as cessation of bleeding, improvement in pelvic pain, resolution of anemia and shrinkage of uterus at week 12.

                                        The symptoms continued to improve with the subsequent 12 weeks of treatment, and the effect lingered at eight weeks following the treatment.

                                        Pending confirmation of the results in additional patients, ObsEva said it may pursue additional studies to support supplemental labeling for the treatment of adenomyosis in reproductive-age women.

                                        1 Reply Last reply Reply Quote 0
                                        • M
                                          maynall44 last edited by

                                          ObsEva Announces Publication of Data Showing Efficacy of Linzagolix in a Potential New Indication for Treatment of Adenomyosis

                                          GENEVA, Switzerland and BOSTON, MA (June 4, 2020) – ObsEva SA (NASDAQ: OBSV) (SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, today reported publication in the journal Fertility and Sterility of “Gonadotropin-releasing Hormone Antagonist (linzagolix): a New Therapy for Uterine Adenomyosis,” a case report from a pilot study assessing the use of linzagolix for the treatment of uterine adenomyosis.

                                          1 Reply Last reply Reply Quote 0
                                          • 1
                                          • 2
                                          • 1 / 2
                                          • First post
                                            Last post
                                          • Medicxi Ventures Management (Jersey) Ltd Buys 3, Sells 2 in 4th ...
                                            news.google.com •

                                          • ObsEva SA (OBSV) expanding its growth trajectory ahead – Sete ...
                                            news.google.com •

                                          • ObsEva SA (OBSV) Reports Q3 Loss, Lags Revenue Estimates
                                            zacks.com •

                                          • Hot Penny Stocks For Your Buy List in September? 3 to Watch
                                            pennystocks.com •

                                          • All You Need to Know About ObsEva SA (OBSV) Rating Upgrade to Buy
                                            zacks.com •

                                          • Why Is ObsEva (OBSV) Stock Down 70% Today?
                                            investorplace.com •

                                          • ObsEva: Ignored, But Long-Term Prospects Exist On Recent Progress
                                            seekingalpha.com •

                                          • ObsEva's (OBSV) Yselty Gets EU Nod to Treat Uterine Fibroids
                                            zacks.com •

                                          • ObsEva SA (OBSV) CEO Brian O'Callaghan on Q1 2022 Results - Earnings Call Transcript
                                            seekingalpha.com •

                                          • 7 Penny Stocks With 10x Potential This Year
                                            investorplace.com •

                                          • ObsEva to Present at the H.C. Wainwright Global Investment 2022 Conference
                                            globenewswire.com •

                                          • What Are the Top 7 Penny Stocks? And Should You Buy?
                                            investorplace.com •

                                          • ObsEva to Host Conference Call and Webcast to Discuss First Quarter 2022 Financial Results and Provide Business Update
                                            globenewswire.com •

                                          • 5 Hot Penny Stocks To Watch With Premarket Momentum & News
                                            pennystocks.com •

                                          • ObsEva Expects Delay In Linzagolix Application Submission In Europe For Uterine Fibroids
                                            benzinga.com •

                                          • Trading Penny Stocks? Top Stock Market News for February 1st, 2022
                                            pennystocks.com •

                                          • Obseva (OBSV) Stock: Why The Price Surged Up Today
                                            pulse2.com •

                                          • 7 Penny Stocks to Buy for January
                                            investorplace.com •

                                          • ObsEva to Present at the H.C. Wainwright BioConnect 2022 Conference
                                            globenewswire.com •

                                          • 7 of the Best Penny Stocks Under $3 for 2022 to Buy Now
                                            investorplace.com •

                                          • Why Are ObsEva Shares Trading Higher Today?
                                            benzinga.com •

                                          • 4 Biotech Penny Stocks to Watch With New Catalysts
                                            pennystocks.com •

                                          • ObsEva Shares Jump After Linzagolix Application For Uterine Fibroids Goes Under FDA Review
                                            benzinga.com •

                                          • Obseva (OBSV) Stock: Why The Price Jumped Today
                                            pulse2.com •

                                          • 7 Penny Stocks to Book Profits on Before 2022
                                            investorplace.com •

                                          • ObsEva Announces Presentation of Clinical Data on Oral GnRH Antagonist Linzagolix at ASRM 2021 Scientific Congress & Expo
                                            globenewswire.com •

                                          • ObsEva Announces Relationship with Syneos Health to Commercialize Linzagolix
                                            globenewswire.com •

                                          • 7 Hot Penny Stocks to Buy in Q4 for 10-Bagger Potential
                                            investorplace.com •

                                          • ObsEva Announces Appointment of Luigi Marro as Chief Transformation Officer
                                            globenewswire.com •

                                          • ObsEva (OBSV) Files NDA for Linzagolix to Treat Uterine Fibroids
                                            zacks.com •

                                          • ObsEva Announces Submission of New Drug Application to U.S. FDA for Linzagolix for the Treatment of Uterine Fibroids
                                            globenewswire.com •

                                          • ObsEva to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
                                            globenewswire.com •

                                          • 5 Penny Stocks To Watch For September With Upcoming Events
                                            pennystocks.com •

                                          • 7 Hottest Penny Stocks to Pick Up Now
                                            investorplace.com •

                                          • ObsEva Announces Second Quarter 2021 Financial Results and Business Update
                                            globenewswire.com •

                                          • ObsEva Announces Two Cornerstone Publications Describing Clinical Trials of Nolasiban for Improving Pregnancy and Live Birth Outcomes Following IVF
                                            globenewswire.com •

                                          • ObsEva to Present at Upcoming Investor Conferences
                                            globenewswire.com •

                                          • OBSV Stock Increases Over 42% Intraday: Why It Happened
                                            pulse2.com •

                                          • Organon and ObsEva Enter Global License Agreement to Develop and Commercialize Ebopiprant (OBE022), an Investigational Agent Being Evaluated as a First-in-Class Treatment for Preterm Labor
                                            globenewswire.com •

                                          • 7 Penny Stocks For Your Watch List This Week If You Like Biotech In July
                                            pennystocks.com •

                                          • ObsEva to Present Ebopiprant (OBE022) Data at the Society for Reproductive Investigation 68th Annual Meeting
                                            globenewswire.com •

                                          • ObsEva Presents Clinical Data on Open-Label Pilot Study of Yselty® (linzagolix) for the Treatment of Severe Adenomyosis at ESHRE Virtual 37th Annual Meeting
                                            globenewswire.com •

                                          • ObsEva To Present Data on Two Clinical Development Programs at ESHRE Virtual 37th Annual Meeting
                                            globenewswire.com •

                                          • ObsEva Presents PROLONG Phase 2a Proof-of-Concept Data on Ebopiprant (OBE022) for the Treatment of Spontaneous Preterm Labor at the RCOG Virtual World Congress 2021
                                            globenewswire.com •

                                          • ObsEva Announces Oral Presentation at the RCOG Virtual World Congress 2021
                                            globenewswire.com •

                                          • ObsEva SA Announces that Shareholders Approved all Board Proposals at its 2021 Annual General Meeting held on May 28, 2021
                                            globenewswire.com •

                                          • ObsEva Announces Proposed Changes to the Composition of its Board of Directors
                                            globenewswire.com •

                                          • ObsEva Announces Final Results from the Phase 3 PRIMROSE Program of Yselty® (linzagolix) for the Treatment of Uterine Fibroids
                                            globenewswire.com •

                                          • ObsEva Announces First Quarter 2021 Financial Results and Business Update
                                            globenewswire.com •

                                          • ObsEva appoints Clive Bertram as Chief Commercial Officer
                                            globenewswire.com •

                                          • ObsEva Announces Enrollment Completion of Linzagolix Phase 3 EDELWEISS 3 Trial for Patients with Moderate to Severe Endometriosis-Associated Pain
                                            globenewswire.com •

                                          • ObsEva SA presents posters at the ACOG Annual Clinical and Scientific Virtual Meeting April 30 - May 2, 2021
                                            globenewswire.com •

                                          • ObsEva Initiates PRIMROSE 3 Bone Mineral Density Follow-Up Study in PRIMROSE 1 and PRIMROSE 2 Trial Participants
                                            globenewswire.com •

                                          • ObsEva Annual General Meeting 2021
                                            globenewswire.com •

                                          • ObsEva Announces Year End 2020 Financial Results and Business Update
                                            globenewswire.com •

                                          • ObsEva to Present at the H.C. Wainwright Global Life Sciences Conference
                                            globenewswire.com •

                                          • ObsEva to Present at the SVB Leerink 10th Annual Global Healthcare Conference
                                            globenewswire.com •

                                          • ObsEva to Increase Issued Share Capital by Creating Additional Treasury Shares
                                            globenewswire.com •

                                          • ObsEva Provides Business Outlook for 2021
                                            globenewswire.com •

                                          • 7 Penny Stocks That Actually Have Buy Ratings
                                            investorplace.com •

                                          • 7 Penny Stock Bubbles That Are About to Burst
                                            investorplace.com •

                                          • ObsEva to Increase Issued Share Capital by Creating Additional Treasury Shares
                                            globenewswire.com •

                                          • Implied Volatility Surging for ObsEva (OBSV) Stock Options
                                            zacks.com •

                                          • OBSV Stock Price Increased 61.51%: Why It Happened
                                            pulse2.com •

                                          • OBSV Stock: 7 Things for ObsEva Investors to Know Before Investing in the Penny Stock
                                            investorplace.com •

                                          • 7 Stocks to Buy With That Second Stimulus Check As More Plan to Save It
                                            investorplace.com •

                                          • ObsEva Provides Update on Yselty® (Linzagolix) Clinical Development Program
                                            globenewswire.com •

                                          • ObsEva appoints David Renas as Chief Financial Officer
                                            globenewswire.com •

                                          • ObsEva Announces Additional Phase 3 PRIMROSE 1 and 2 Study Results Confirming Sustained Efficacy and Continued Safety of linzagolix in the Treatment of Uterine Fibroids
                                            globenewswire.com •

                                          • ObsEva SA to present at The International Society of Gynecological Endocrinology 19th World Congress – virtual edition, December 2-5, 2020
                                            globenewswire.com •

                                          • ObsEva SA Submits Marketing Authorization Application to the European Medicines Agency for YSELTY® (linzagolix) for the Treatment of Women with Uterine Fibroids
                                            globenewswire.com •

                                          • ObsEva SA Reports Positive Topline Results of the PROLONG Proof-of-Concept Trial of Ebopiprant (OBE022) for Treatment of Preterm Labor
                                            globenewswire.com •

                                          • ObsEva SA to present at Jefferies Virtual London Healthcare Conference, November 17 – 19, 2020
                                            globenewswire.com •

                                          • ObsEva appoints Brian O'Callaghan as Chief Executive Officer
                                            globenewswire.com •

                                          • ObsEva SA hosts live symposium and presents oral communication at the SEUD Online Week November 3 - 6, 2020
                                            globenewswire.com •

                                          • ObsEva SA to present at the Wedbush PacGrow Healthcare Virtual Conference, August 11 – 12, 2020
                                            finance.yahoo.com •

                                          • ObsEva Announces Second Quarter 2020 Financial Results and Business Update
                                            finance.yahoo.com •

                                          • ObsEva SA Awarded Clinical Science Award for Oral Presentation at ESHRE Virtual 36th Annual Meeting, July 2020
                                            finance.yahoo.com •

                                          • The Week Ahead In Biotech: Endo, Eagle Pharma FDA Decisions, ObsEva Late-Stage Readouts In Focus
                                            finance.yahoo.com •

                                          • ObsEva Announces Positive Results from two Phase 3 Studies, PRIMROSE 1 and 2, of Yselty® (linzagolix) for the Treatment of Uterine Fibroids
                                            finance.yahoo.com •

                                          • ObsEva SA to present at ESHRE Virtual 36th Annual Meeting, July 5-8, 2020
                                            finance.yahoo.com •

                                          • ObsEva and Yuyuan BioScience Technology Announce Submission of the Pre-IND Dossier for Nolasiban with the Chinese NMPA
                                            finance.yahoo.com •

                                          • ObsEva SA to Hold Conference Call Monday, July 6 to Discuss Results from Phase 3 PRIMROSE 1 and PRIMROSE 2 Trials Evaluating Linzagolix in Women with Uterine Fibroids
                                            finance.yahoo.com •

                                          • Is ObsEva SA (OBSV) A Good Stock To Buy?
                                            finance.yahoo.com •

                                          • ObsEva SA Announces that Shareholders Approved all Board Proposals at its 2020 Annual General Meeting held on June 9, 2020
                                            finance.yahoo.com •

                                          • The Daily Biotech Pulse: Positive Readout For Kezar, AstraZeneca Stitches Oncology Partnership, D-Day For Merck's Triple Combo Antibiotic
                                            finance.yahoo.com •

                                          • ObsEva Announces Publication of Data Showing Efficacy of Linzagolix in a Potential New Indication for Treatment of Adenomyosis
                                            finance.yahoo.com •

                                          • ObsEva SA to present at the Jefferies Virtual Healthcare Conference June 3rd, 2020
                                            finance.yahoo.com •

                                          • New Forecasts: Here's What Analysts Think The Future Holds For ObsEva SA (NASDAQ:OBSV)
                                            finance.yahoo.com •

                                          • ObsEva Annual General Meeting 2020
                                            finance.yahoo.com •

                                          • Here's What Analysts Are Forecasting For ObsEva SA (NASDAQ:OBSV) After Its First-Quarter Results
                                            finance.yahoo.com •

                                          • These 3 Biotech Stocks Have Massive Upside Potential, Says Wedbush
                                            finance.yahoo.com •

                                          • ObsEva Announces First Quarter 2020 Financial Results and Business Update
                                            finance.yahoo.com •

                                          • Analysts Offer Insights on Healthcare Companies: ObsEva SA (OBSV) and Homology Medicines (FIXX)
                                            smarteranalyst.com •

                                          • Analysts Offer Insights on Healthcare Companies: ObsEva SA (NASDAQ: OBSV) and Homology Medicines (NASDAQ: FIXX)
                                            markets.co •

                                          • Goldman Sachs Group Inc. Sells 48,929 Shares of Obseva SA (NASDAQ:OBSV)
                                            thelincolnianonline.com •

                                          • How ObsEva (OBSV) Stock Stands Out in a Strong Industry
                                            finance.yahoo.com •

                                          • How ObsEva (OBSV) Stock Stands Out in a Strong Industry
                                            zacks.com •

                                          • The Daily Biotech Pulse: FDA Nod For Immunomedics, Lilly's Solid Q1 Beat, Predictive Oncology Restructures Debt
                                            finance.yahoo.com •

                                          • ObsEva up 10% after hours on long-term linzagolix data
                                            seekingalpha.com •

                                          Copyright © 2022 finabase.io